Literature DB >> 20414202

Phosphoinositide signalling in cancer: beyond PI3K and PTEN.

Tom D Bunney1, Matilda Katan.   

Abstract

There are numerous studies that suggest multiple links between the cellular phosphoinositide system and cancer. As key roles in cancer have been established for PI3K and PTEN - enzymes that regulate the levels of phosphatidylinositol-3,4,5-trisphosphate - compounds targeting this pathway are entering the clinic at a rapid pace. Several other phosphoinositide-modifying enzymes, including phosphoinositide kinases, phosphatases and phospholipase C enzymes, have been implicated in the generation and progression of tumours. Studies of these enzymes are providing new insights into the mechanisms and the extent of their involvement in cancer, highlighting new potential targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20414202     DOI: 10.1038/nrc2842

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  121 in total

1.  Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin.

Authors:  Ernesto Andrianantoandro; Thomas D Pollard
Journal:  Mol Cell       Date:  2006-10-06       Impact factor: 17.970

Review 2.  Regulation of the actin cytoskeleton by phosphatidylinositol 4-phosphate 5 kinases.

Authors:  Yuntao S Mao; Helen L Yin
Journal:  Pflugers Arch       Date:  2007-05-23       Impact factor: 3.657

Review 3.  Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions.

Authors:  Robert H Michell; Victoria L Heath; Mark A Lemmon; Stephen K Dove
Journal:  Trends Biochem Sci       Date:  2005-12-20       Impact factor: 13.807

4.  Phosphatidylinositol-4-phosphate 5-kinase gamma is associated with cell-cell junction in A431 epithelial cells.

Authors:  Chiyuki Akiyama; Naeko Shinozaki-Narikawa; Takatoshi Kitazawa; Takao Hamakubo; Tatsuhiko Kodama; Yoshikazu Shibasaki
Journal:  Cell Biol Int       Date:  2005-07       Impact factor: 3.612

5.  Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

Authors:  S Barnache; E Le Scolan; O Kosmider; N Denis; F Moreau-Gachelin
Journal:  Oncogene       Date:  2006-03-02       Impact factor: 9.867

Review 6.  PIP5K-driven PtdIns(4,5)P2 synthesis: regulation and cellular functions.

Authors:  Iman van den Bout; Nullin Divecha
Journal:  J Cell Sci       Date:  2009-11-01       Impact factor: 5.285

7.  Overexpression of phospholipase C-gamma 1 in familial adenomatous polyposis.

Authors:  J G Park; Y H Lee; S S Kim; K J Park; D Y Noh; S H Ryu; P G Suh
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

8.  The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion.

Authors:  Gianpaolo Suriano; David Mulholland; Olivier de Wever; Paulo Ferreira; Ana Rita Mateus; Eric Bruyneel; Colleen C Nelson; Marc M Mareel; Jun Yokota; David Huntsman; Raquel Seruca
Journal:  Oncogene       Date:  2003-08-28       Impact factor: 9.867

Review 9.  Understanding PTEN regulation: PIP2, polarity and protein stability.

Authors:  N R Leslie; I H Batty; H Maccario; L Davidson; C P Downes
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

10.  E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer.

Authors:  Tomonori Yabuta; Kazuya Shinmura; Masachika Tani; Satoru Yamaguchi; Kimio Yoshimura; Hitoshi Katai; Takashi Nakajima; Erito Mochiki; Toshimasa Tsujinaka; Motohisa Takami; Kazuo Hirose; Akio Yamaguchi; Seiichi Takenoshita; Jun Yokota
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

View more
  181 in total

1.  [Combined treatment with myo-inositol and luteolin selectively suppresses growth of human lung cancer A549 cells possibly by suppressing activation of PDK1 and Akt].

Authors:  Yun Wang; Yuyuan Zhang; Xue Chen; Yun Hong; Zhengdong Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

Review 2.  [Tumor stem cell research - basis and challenge for diagnosis and therapy].

Authors:  Heidrun Karlic; Harald Herrmann; Axel Schulenburg; Thomas W Grunt; Sylvia Laffer; Irina Mirkina; Rainer Hubmann; Medhat Shehata; Brigitte Marian; Edgar Selzer; Michael Pfeilstöcker; Elisabeth Pittermann; Ulrich Jäger; Hubert Pehamberger; Christoph Zielinski; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2010-07-22       Impact factor: 1.704

Review 3.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

4.  Targeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies.

Authors:  Jonathan H Schatz
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 5.  Toll-like receptors, signaling adapters and regulation of the pro-inflammatory response by PI3K.

Authors:  Ty Dale Troutman; J Fernando Bazan; Chandrashekhar Pasare
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

6.  A rare eicosanoid precursor analogue, sciadonic acid (5Z,11Z,14Z-20:3), detected in vivo in hormone positive breast cancer tissue.

Authors:  H G Park; J Y Zhang; C Foster; D Sudilovsky; D A Schwed; J Mecenas; S Devapatla; P Lawrence; K S D Kothapalli; J T Brenna
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2018-05-16       Impact factor: 4.006

7.  Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy.

Authors:  Ashish Kulkarni; Bhaskar Roy; Ambarish Pandey; Aaron Goldman; Sasmit Sarangi; Poulomi Sengupta; Colin Phipps; Jawahar Kopparam; Michael Oh; Sudipta Basu; Mohammad Kohandel; Shiladitya Sengupta
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

8.  Targeting the target of rapamycin (TOR): looking to mother nature.

Authors:  Eric K Rowinsky
Journal:  Target Oncol       Date:  2011-04-27       Impact factor: 4.493

9.  Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Authors:  Myles C Hodgson; Long-jiang Shao; Anna Frolov; Rile Li; Leif E Peterson; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

10.  Novel agents in indolent lymphomas.

Authors:  Michele Merli; Andrea Ferrario; Claudia Basilico; Margherita Maffioli; Domenica Caramazza; Lorena Appio; Luca Arcaini; Francesco Passamonti
Journal:  Ther Adv Hematol       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.